uniQure Advances AMT-130 Toward UK Approval for Huntington’s Disease
Patients facing the devastating impact of Huntington’s disease may be one step closer to a transformative treatment. UniQure N.V. Recently announced the completion of a successful Pre-Submission Meeting with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), signaling a clear path toward seeking formal approval for its gene therapy, AMT-130.
The company now expects to submit a Marketing Authorization Application (MAA) in the third quarter of 2026. This move represents a strategic push to bring the therapy to the UK market, utilizing data from ongoing international clinical trials to support the filing.
The Road to Regulatory Approval in the UK
A Pre-Submission Meeting is a critical early-stage dialogue between a pharmaceutical company and a regulator. In this instance, uniQure and the MHRA focused on the specific data package and manufacturing requirements necessary to support a formal application. This process ensures that the evidence provided is sufficient for the agency to evaluate the safety and efficacy of the drug before the official review begins.
According to Matt Kapusta, chief executive officer of uniQure, the feedback from the MHRA was “constructive.” Kapusta noted that this progress is “an crucial milestone for the Huntington’s disease community,” reaffirming the company’s commitment to working with global regulators to deliver the therapy to patients internationally.
Clinical Data Driving the Submission
The upcoming MAA submission won’t be based on guesswork; it will be supported by a three-year analysis from ongoing Phase I/II clinical trials conducted across the United States and Europe. By analyzing long-term data, uniQure aims to demonstrate the sustained impact of AMT-130 on the progression of Huntington’s disease.
A Broader Global Strategy
While the UK filing is a primary focus, uniQure is pursuing a multi-pronged global regulatory strategy. The company is actively exploring additional ex-US regulatory pathways to ensure the therapy can reach international markets efficiently.
In the United States, uniQure has been granted a Type B Meeting with the FDA, scheduled for the second quarter of 2026. This meeting will focus on the potential design and analysis plan for a Phase III trial, specifically examining four-year data for AMT-130.
- UK Filing Timeline: uniQure plans to submit its Marketing Authorization Application (MAA) to the MHRA in Q3 2026.
- Evidence Base: The submission will rely on three-year analysis data from Phase I/II trials in the US and Europe.
- US Progress: A Type B meeting with the FDA is set for Q2 2026 to discuss Phase III trial designs.
- Global Reach: The company is pursuing multiple international regulatory routes to expand patient access.
Frequently Asked Questions
What is AMT-130?
AMT-130 is an investigational gene therapy developed by uniQure designed to treat Huntington’s disease, a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of cognitive ability.
What is a Marketing Authorization Application (MAA)?
An MAA is the formal application submitted to a regulatory body—such as the MHRA in the UK—to request permission to market a medicinal product. It requires comprehensive data on the drug’s quality, safety, and efficacy.
Why is the MHRA meeting significant?
The Pre-Submission Meeting reduces regulatory risk by aligning the company’s data collection and manufacturing processes with the regulator’s expectations, streamlining the path to potential patient access.
Looking Ahead
The transition from Phase I/II trials toward a formal MAA submission in the UK marks a pivotal shift for AMT-130. As uniQure prepares its Q3 2026 filing and engages with the FDA on Phase III designs, the coming year will be decisive in determining if this gene therapy becomes a standard of care for those living with Huntington’s disease.